Molecular therapy for cardiac dysfunction: Empagliflozin (trade name: Jardiance), used in the treatment of TIIDM, decreases Mir-29 expression, activates Wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function, via upregulation of its target gene, 15/November/2018, 11.22 pm